Carbohydrate Metabolism and Lactate
1 Glucose Utilization
Abnormal glucose handling occurs in ME/CFS:
- Hypoglycemia symptoms: Reported by many patients, though blood glucose often normal
- Impaired glucose uptake: May affect specific tissues
- Altered insulin sensitivity: Variable findings
- Post-prandial symptoms: Reactive responses to meals
2 Lactate Accumulation
Elevated lactate indicates reliance on anaerobic metabolism:
- Resting lactate: May be elevated in some patients
- Exercise lactate: Earlier and greater accumulation
- Recovery: Slower lactate clearance
- Brain lactate: Elevated on MR spectroscopy in some studies
Clinical Phenomenology: Similarities to Athletic Post-Exercise States.
The chronic lactate accumulation and reliance on anaerobic metabolism in ME/CFS produces a muscle metabolic state remarkably similar to what elite athletes experience temporarily after exhausting physical efforts:
- Muscle cramping: ATP depletion prevents proper muscle relaxation; magnesium and calcium handling disrupted
- “Ready for cramps” sensation: Persistent partial ATP deficit maintains muscles in pre-cramp tension state
- Metabolic acidosis: Lactate accumulation creates acidic intracellular environment
- Delayed recovery: Impaired lactate clearance prolongs metabolic stress
The critical difference: athletes experience this state transiently after intense exertion and recover within hours to days; ME/CFS patients exist in this state continuously, even at rest or after minimal activity.
This parallel has practical treatment implications. Sports medicine recovery protocols—electrolyte replacement, magnesium supplementation, ATP precursors (D-ribose), lactate clearance strategies—may provide symptomatic benefit by addressing the chronic metabolic stress state. These recovery strategies informed the development of baseline metabolic support protocols discussed in the treatment chapters.
ME/CFS muscle pathophysiology may be understood as a state of continuous post-exercise metabolic stress without the triggering exercise. Interventions that support athletic recovery from intense exertion may provide baseline metabolic support for ME/CFS patients:
- Oral rehydration solutions for blood volume and lactate clearance
- Magnesium for ATP synthesis and muscle relaxation
- Acetyl-L-carnitine to restore fat oxidation capacity
- D-ribose as direct ATP building block
This framework suggests ME/CFS patients require continuous application of recovery protocols, not as performance enhancement but as compensatory support for chronically impaired energy metabolism.
Certainty: 0.40. (Raw certainty 0.40 — Vienna preprint, not yet peer-reviewed, n=26 patients / 27 controls; ME/CFS population weight 1.0 → discounted 0.40.) A proof-of-concept multimodal MRI study exposed ME/CFS patients and controls to normoxia plus two controlled hypoxic challenges (SpO2 ~87%) while measuring cerebral metabolites and blood flow (Bader et al. 2026). Patients showed an elevated resting thalamic lactate-to-creatine ratio (Lac/tCr) at baseline: 0.171 vs 0.135 in controls (~27% higher; \(\beta\)=0.035, \(p\)=0.021); white-matter Lac/tCr did not differ. Under hypoxia, control thalamic Lac/tCr rose (H1 \(p\)=0.028, H2 \(p\)=0.039), but patients’ did not (H1 \(p\)=0.38, H2 \(p\)=0.46) — already elevated at baseline. Because the “blunted” patient response is a null (a failure to detect a rise in a modest sample), it should not be read as strongly as a demonstrated group difference; a ceiling or regression-to-the-mean effect (patients already elevated, leaving less room to rise) is a plausible alternative to genuine blunted reactivity. This is consistent with the “virtual hypoxia” hypothesis: the brain behaves as if under chronic oxygen limitation despite normal arterial oxygenation, reflecting intrinsic mitochondrial/bioenergetic inefficiency with a glycolytic shift (Trapp and Stys 2009) (Tomas et al. 2017). The authors note that elevated baseline brain lactate is “consistent with the most reproducible spectroscopic finding in ME/CFS — increased ventricular and cerebral lactate” (Bader et al. 2026).
Replication status: Not yet replicated. This is a single preprint; the finding is consistent with prior spectroscopy evidence of elevated brain lactate but the specific blunted-reactivity pattern is novel.
Severity applicability: Unknown — the study cohort was not stratified by severity; whether the resting-lactate elevation and blunted metabolic reactivity differ across disease severity levels is not established.
Limitations: Proof-of-concept design with a modest sample; cross-sectional; the hypoxic challenge is a controlled physiological stressor and cannot be directly attributed to post-exertional malaise, because it is not physical exertion. The blunted-reactivity claim rests on a null patient response that could reflect a ceiling/regression-to-mean effect rather than genuine impaired reactivity. Exploratory analyses (network coupling) are hypothesis-generating.
Falsifiable prediction: If virtual hypoxia reflects intrinsic bioenergetic inefficiency, then resting brain lactate should remain elevated (or show a blunted rise) in patients across a second independent cohort, and an intervention that restores mitochondrial ATP production (e.g., metabolic support targeting the PDH/glycolytic balance) should normalise the resting lactate signal.
Consequence: This finding supports the view that ME/CFS fatigue is accompanied by a measurable brain metabolic signature — an inability to ramp up energy production on demand — rather than purely psychological or motivational causes, and gives researchers a concrete imaging readout to track.
The experimental-hypoxia probe and its cross-disease framing suggest that ME/CFS may involve a brain behaving as if under chronic energy limitation despite normal arterial oxygenation — a “virtual hypoxia” state of impaired neuro-metabolic adaptive capacity (Bader et al. 2026). These environments are internally consistent — elevated resting brain lactate that fails to ramp up under a controlled hypoxic stressor (Virtual Hypoxia: Elevated Resting Brain Lactate with Blunted Metabolic Reactivity) and preserved gross cerebrovascular reactivity but greater initial response variability (Preserved Gross Cerebrovascular Reactivity but Greater Inter-Individual Variability) both derive from the same single preprint, and the pattern extends the bioenergetic-inefficiency logic developed in multiple sclerosis as a mechanistic bridge rather than an identity (Multiple Sclerosis “Virtual Hypoxia” as a Mechanistic Template — Not an Identity). They should not be read as independent replications: this is one proof-of-concept study plus a conceptual bridge, not three converging bodies of evidence. Two constraints remain open: the direction of any brainstem volume difference is unresolved across cohorts (Brainstem Volume Direction Contradicts Across Cohorts), and whether elevated brain lactate can stratify patients for tissue-oxygenation or mitochondrial-targeted trials is hypothesis-generating, not validated (Thalamic Lac/tCr as a Candidate Stratification Biomarker for Energy-Metabolism Trials). What the evidence supports is a measurable, mechanism-proximal brain metabolic signature of the disease; what remains speculative is its causal role, its severity stratification, and any therapeutic implication. The most important open question is whether this resting metabolic signature is a cause of ME/CFS fatigue or a downstream epiphenomenon of a more proximal defect.
Consequence: These findings give researchers and clinicians a concrete, mechanism-anchored brain readout — elevated resting lactate and a blunted metabolic response to challenge — that could eventually help define a biologically distinct “brain-energy-deficient” subgroup, but only after independent replication and prospective validation; they do not yet support any treatment recommendation.
3 Insulin Sensitivity
Insulin resistance features in some ME/CFS patients:
- Hyperinsulinemia: Compensatory insulin excess
- Impaired glucose tolerance: Abnormal oral glucose tolerance tests
- Metabolic syndrome overlap: Shared features in some patients
- Inflammation link: Cytokines promote insulin resistance